Potential protective effect of long-term therapy with xuezhikang on left ventricular diastolic function in patients with essential hypertension

Journal of Alternative and Complementary Medicine

Volumn 15, Issue 7, 2009, Pages 719-725

  Ye, Ping ^a   Wu, Cai E ^a   Sheng, Li ^a   Li, Hui ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL TYPE 1 PROCOLLAGEN PROPEPTIDE; CHOLESTEROL; COLLAGEN TYPE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; UNCLASSIFIED DRUG; XUEZHIKANG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FLOW RATE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART MOVEMENT; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TISSUE DOPPLER IMAGING; TREATMENT OUTCOME;

AGED; BIOLOGICAL PRODUCTS; BLOOD FLOW VELOCITY; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DIASTOLE; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MITRAL VALVE; NIFEDIPINE; SINGLE-BLIND METHOD; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67749127820     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2008.0599     Document Type: Article

References (31)

1. Verdecchia P, Schillaci G, Guerrieri M, et al. Prevalence and determinants of left ventricular diastolic filling abnormalities in an unselected hypertensive population. Eur Heart J 1990; 11:679-691.
2. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
3. Aeschbacher BC, Hutter D, Fuhrer J, et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001;14:106-113.
4. Sato A, Hayshi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002;25:837-842.
5. Devereux RB, Palmieri V, Sharpe N, et al. Effects of oncedaily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001;104:1248-1254.
6. Entok E, Unalir A, Cavusoglu Y, et al. Long-term effects of antilipidaemic therapy on left ventricular function in patients with dyslipidaemia: Multigated radionuclide ventri-culography study. Nucl Med Commun 2005;26:773-779.
7. Su SF, Hsiao CL, Chu CW, et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000;86:514-518.
8. Oh JK, Appleton CP, Hatle LK, et al. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997;10:246-270.
9. Waggoner AD, Bierig SM. Tissue Doppler imaging: A useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 2001;14:1143-1152.
10. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proc 2008;83:758-764.
11. Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5225.
12. Zhao SP, Liu L, Cheng YC, Li YL. Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 2003;168:375-380.
13. Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004;110:915-920.
14. Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: A shortterm time course study in patients with stable angina. Clin Chim Acta 2005;352:217-224.
15. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implication of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-239.
16. Devereux RB, Alonso DR, Lutas EM, et al. Echocardio-graphic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
17. D́iez J, Laviades C, Mayor G, et al. Increased serum concentrations of procollagen peptides in essential hypertension: Relation to cardiac alterations. Circulation 1995;91:1450-1456.
18. Ye P, Li JJ, Su G, Zhang C. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hy-pertriglyceridemia. Clinica Chimica Acta 2005;356:229-232.
19. Maron BJ, Spirito P, Green KJ, et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomy-opathy. J Am Coll Cardiol 1987;10:733-742.
20. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997;30:8-18.
21. Vogel M, Anderson LJ, Holden S, et al. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003;24:113-119.
22. Lu Z, Kou W, Du B, et al. Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689-1693.
23. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002;27:92-98.
24. Sciarretta S, Ferrucci A, Ciavarella GM, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007;20:784-791.
25. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28:483-490.
26. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105: 868-873.
27. López B, González A, Varo N, et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-1226.
28. Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004;110: 1263-1268.
29. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46.
30. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and dia-stolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19:303-309.
31. Takahashi M, Minatoguchi S, Nishigaki K, et al. Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: An evaluation using a novel indicator of burden on the left ventricle. Hypertens Res 2006;29:89-94.